A systematic review of medical interventions for oral submucous fibrosis and future research opportunities

Oral Diseases

Volumn 17, Issue SUPPL. 1, 2011, Pages 42-57

  Kerr, Ar ^a   Warnakulasuriya, S ^b   Mighell, Aj ^c   Dietrich, T ^d   Nasser, M ^e   Rimal, J ^f   Jalil, A ^g   Bornstein, Mm ^h   Nagao, T ⁱ   Fortune, F ^j   Hazarey, Vh ^k   Reichart, Pa ^h   Silverman, S ^l   Johnson, Nw ^m  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^f B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^g INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ Okazaki City Hospital   (Japan)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k GOVERNMENT DENTAL COLLEGE AND HOSPITAL   (India)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m GRIFFITH UNIVERSITY   (Australia)

more..

Author keywords

Management; Medical interventions; Oral submucous fibrosis; Research; Systematic review

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BETAMETHASONE; BUFLOMEDIAL HYDROCHLORIDE; BUPHENINE; CHYMOTRYPSIN; COLLAGENASE; COPPER; DANXUAN KOUKANG; DEXAMETHASONE; FERROUS FUMARATE; HYALURONIDASE; HYDROCORTISONE; IRON; LEVAMISOLE; MAGNESIUM; METHYLPREDNISOLONE; MULTIVITAMIN; NICOTINIC ACID; PENTOXIFYLLINE; PLACENTA EXTRACT; RECOMBINANT GAMMA INTERFERON; RETINOL; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE DIACETATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN B COMPLEX; VITAMIN D; ZINC;

ARTICLE; DIETARY INTAKE; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; MEDLINE; MOUTH DISEASE; MOUTH PAIN; MOUTH ULCER; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TONGUE DISEASE;

DENTAL RESEARCH; FORECASTING; HUMANS; ORAL SUBMUCOUS FIBROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 79952495191     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01791.x     Document Type: Article

References (66)

1. Ariyawardana A, Nawagamuwa T, Ranasinghe AJ, Sitheeque M, Vithanaarachchi N (2005). Conservative management of oral submucous fibrosis. Asian J Oral Maxillofac Surg 17: 26-30.
2. Bjordal K, de Graeff A, Fayers PM et al (2000). A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 36: 1796-1807.
3. Borle RM, Borle SR (1991). Management of oral submucous fibrosis: a conservative approach. J Oral Maxillofac Surg 49: 788-791.
4. Brown P, Brunnhuber K, Chalkidou K et al (2006). How to formulate research recommendations. BMJ 333: 804-806.
5. Cai W, Chen X (2006). Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Curr Med Chem Anticancer Agents 6: 407-428.
6. Chainani-Wu N (2003). Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Alternat Complement Med 9: 161-168.
7. Chen HR, Lin HJ (1986). Clinicopathologic study on submucosal injection of collagenase in the treatment of submucous fibrosis in the oral cavity. Kaohsiung J Med Sci 2: 212-219.
8. Chen Z-L, Chen H-b, Huang W-x, Huang Q (2006). The clinical effect of microwave radiation in treating oral mucous membrane diseases. J Clin Stomatol 22: 750.
9. Cox S, Zoellner H (2009). Physiotherapeutic treatment improves oral opening in oral submucous fibrosis. J Oral Pathol Med 38: 220-226.
10. Epstein J, Sanderson IR, Macdonald TT (2010). Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103: 1545-1557.
11. Fedorowicz Z, Chan Shih-Yen E, Dorri M, Nasser M, Newton T, Shi L (2009). Interventions for the management of oral submucous fibrosis. Cochrane Database Syst Rev Vol 1. CD007156.
12. Gupta PC, Ray CS (2003). Smokeless tobacco and health in India and South Asia. Respirology 8: 419-431.
13. Gupta D, Sharma SC (1988). Oral submucous fibrosis - a new treatment regimen. J Oral Maxillofac Surg 46: 830-833.
14. Gupta PC, Warnakulasuriya S (2002). Global epidemiology of areca nut usage. Addiction Biology 7: 77-83.
15. Gupta DS, Gupta MK, Golhar BL (1980). Oral submucous fibrosis - clinical study and management with physiofibrolysis (MWD). J Indian Dent Assoc 52: 375-378.
16. Gupta DCS, Rameshwar D, Iqbal A (1992). Treatment modalities in oral submucous fibrosis: how they stand today? Study of 600 cases. Indian J Oral Maxillofac Surg 7: 43-47.
17. Gupta PC, Hebert JR, Bhonsle RB, Sinor PN, Mehta H, Mehta FS (1998). Dietary factors in oral leukoplakia and submucous fibrosis in a population-based case control study in Gujarat, India. Oral Dis 4: 200-206.
18. Gupta PC (1999) Mouth cancer in India: A new epidemic. J Indian Med Assoc 97: 370-373.
19. Guyatt GH, Oxman AD, Vist GE et al (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924-926.
20. Haque MF, Meghji S, Nazir R, Harris M (2001). Interferon gamma (IFN-gamma) may reverse oral submucous fibrosis. J Oral Pathol Med 30: 12-21.
21. Hastak K, Lubri N, Jakhi SD et al (1998). Therapeutic responses to turmeric oil and turmeric oleoresin in oral submucos fibrosis. Amala Res Bulletin 18: 23-28.
22. Hayes PA (1985). Oral submucous fibrosis in a 4-year-old girl. Oral Surg Oral Med Oral Pathol 59: 475-478.
23. Higgins JPT, Green S (2009). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009.
24. Huang IY, Wu C-F, Shen Y-S et al (2008). Importance of patient's cooperation in surgical treatment for oral submucous fibrosis. J Oral Maxillofac Surg 66: 699-703.
25. International Agency for Research on Cancer (2004). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 85. Lyon; France: Betel-quid and Areca-nut Chewing and Some Areca-nut-derived Nitrosamines.
26. Jaeschke R, Guyatt GH, Dellinger P et al (2008). Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 337: a744.
27. Jiang X, Hu J (2009). Drug treatment of oral submucous fibrosis: a review of the literature. J Oral Maxillofac Surg 67: 1510-1515.
28. Jirge V, Shashikanth MC, Ali IM, Anshumalee N (2008). Levamisole and antioxidants in the mangement of oral submucous fibrosis: a comparative study. J Indian Acad Oral Med Radiol 20: 135-140.
29. Joshi J, Ghaisas SD, Vaidya A et al (2003). Early human safety of tumeric oil (Curcuma longa oil) administered orally in healthy volunteers. JAPI 51: 1055-1060.
30. Kakar PK, Puri RK, Venkatachalam VP (1985). Oral submucous fibrosis - treatment with hyalase. J Laryngol Otol 99: 57-59.
31. Katharia SK, Singh SP, Kulshreshtha VK (1992). The effects of placenta extract in management of oral submucous fibrosis. Indian J Pharmacol 24: 181-183.
32. Khanna JN, Andrade NN (1995). Oral submucous fibrosis: a new concept in surgical management. Report of 100 cases. Int J Oral Maxillofac Surg 24: 433-439.
33. Kumar N, Sharma SC, Sharma P, Chandra OM, Singhal KC, Nagar A (1991). Beneficial effect of oral zinc in the treatment of oral submucous fibrosis. Indian J Pharmacol 23: 236-241.
34. Kumar A, Bagewadi A, Keluskar V, Singh M (2007). Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103: 207-213.
35. Lai DR, Chen HR, Lin LM, Huang YL, Tsai CC (1995). Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases. J Oral Pathol Med 24: 402-406.
36. Le PV, Gornitsky M, Domanowski G (1996). Oral stent as treatment adjunct for oral submucous fibrosis. [Erratum appears in Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Nov;82(5):536]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81: 148-150.
37. Li XI, Tang JI (1998). Clinical treatment observation of tea pigment for oral submucous fibrosis. Huaxi Kouqiang Yixue Zazhi 16: 50-52.
38. Lin HJ, Lin JC (2007). Treatment of oral submucous fibrosis by collagenase: effects on oral opening and eating function. Oral Dis 13: 407-413.
39. List MA, D'Antonio LL, Cella DF et al (1996). The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. A study of utility and validity. Cancer 77: 2294-2301.
40. Liu SF, Shen TH, Tang ZG, Su HP, Luo CF (1999). On treatment of oral submucous fibrosis with glucosidorum tripterygii totorum. Beijing J Stomatol 7: 167-169.
41. Maher R, Sankaranarayanan R, Johnson NW, Warnakulasuriya S (1996). Evaluation of inter-incisor distance as an objective criterion of the severity of oral submucous fibrosis in Karachi, Pakistan. Oral Oncology 32B: 362-364.
42. Maher R, Aga P, Johnson NW, Sankaranarayanan R, Warnakulasuriya S (1997). Evaluation of multiple micronutrient supplementation in the management of oral submucous fibrosis in Karachi, Pakistan. Nutr Cancer 27: 41-47.
43. Moher D, Schulz KF, Altman D, Group C (2001). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285: 1987-1991.
44. Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS (1985). Malignant transformation rate in oral submucous fibrosis over a 17-year period. Commun Dent Oral Epidemiol 13: 340-341.
45. Nayak DR, Mahesh SG, Aggarwal D, Pavithran P, Pujary K, Pillai S (2009). Role of KTP-532 laser in management of oral submucous fibrosis. J Laryngol Otol 123: 418-421.
46. Patil PG, Parkhedkar RD (2009). New graft-stabilizing clip as a treatment adjunct for oral submucous fibrosis. J Prosthet Dent 102: 191-192.
47. Pindborg JJ, Sirsat SM (1966). Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 22: 765-779.
48. Prucksunand C, Indrasukhsri B, Leethochawalit M, Hungspreugs K (2001). Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer. Southeast Asian J Trop Med Public Health 32: 208-215.
49. Rai B, Kaur J, Jacobs R, Singh J (2010). Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci 52: 251-256.
50. Rajalalitha P, Vali S (2005). Molecular pathogenesis of oral submucous fibrosis - a collagen metabolic disorder. J Oral Pathol Med 34: 321-328.
51. Rajendran R, Rani V, Shaikh S (2006). Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res 17: 190-198.
52. Ranganathan K, Mishra G (2006) An overview of classification schemes for oral submucous fibrosis. J Oral and Maxillo Facial Pathology 10: 55-58.
53. Rananjaneyulu P, Rao P (1980). Submucous fibrosis - new treatment. J Indian Dent Assoc 52: 379-380.
54. Schwartz J (1952). Atrophia idiopathica (tropica) mucosaeoris oris. London: Proceedings of the 11th International Dental Congress, 1952.
55. Sharma JK, Gupta AK, Mukhija RD, Nigam P (1987). Clinical experience with the use of peripheral vasodilator in oral disorders. Int J Oral Maxillofac Surg 16: 695-699.
56. Shehzad A, Wahid F, Lee YS (2010). Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343: 489-499.
57. Singh M, Niranjan HS, Mehrotra R, Sharma S, Gupta SC (2010). Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis. Indian J Med Res 131: 665-669.
58. Tai YS, Liu BY, Wang JT, Sun A, Kwan HW, Chiang CP (2001). Oral administration of milk from cows immunized with human intestinal bacteria leads to significant improvements of symptoms and signs in patients with oral submucous fibrosis. J Oral Pathol Med 30: 618-625.
59. Talsania JR, Shah UB, Shah AI, Singh NK (2009). Use of diode laser in oral submucous fibrosis with trismus: prospective clinical study. Indian J Otolaryngol Head Neck Surg 61(Suppl. 1): 22-25.
60. Tan J, Li YC, Chen A et al (2006). Clinical research of danxuan koukang on treatment of oral submucous fibrosis. J Traditional Chinese Med University of Hunan 26: 41-43.
61. Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S (2006). Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42: 561-568.
62. Tschiesner U, Becker S, Cieza A (2010). Health professional perspective on disability in head and neck cancer. Arch Otolaryngol Head Neck Surg 136: 576-583.
63. Warnakulasuriya S (1987). Semi-quantitative clinical description of oral submucous fibrosis. Ann Dent 46: 18-21.
64. Warnakulasuriya S, Johnson NW, van der Waal I (2007). Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36: 575-580.
65. Wewers ME, Lowe NK (1990). A critical review of visual analogue scales in the measurement of clinical phenomena. Research in Nursing and Health 13: 227-236.
66. Winstock A (2002). Areca nut-abuse liability, dependence and public health. Addict Biol 7: 133-138.